161 related articles for article (PubMed ID: 8706771)
1. Improved pharmacodynamics of L-asparaginase-loaded in human red blood cells.
Kravtzoff R; Desbois I; Lamagnere JP; Muh JP; Valat C; Chassaigne M; Colombat P; Ropars C
Eur J Clin Pharmacol; 1996; 49(6):465-70. PubMed ID: 8706771
[TBL] [Abstract][Full Text] [Related]
2. L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL).
Kwon YM; Chung HS; Moon C; Yockman J; Park YJ; Gitlin SD; David AE; Yang VC
J Control Release; 2009 Nov; 139(3):182-9. PubMed ID: 19577600
[TBL] [Abstract][Full Text] [Related]
3. Tolerance evaluation of L-asparaginase loaded in red blood cells.
Kravtzoff R; Colombat PH; Desbois I; Linassier C; Muh JP; Philip T; Blay JY; Gardenbas M; Poumier-Gaschard P; Lamagnere JP; Chassaigne M; Ropars C
Eur J Clin Pharmacol; 1996; 51(3-4):221-5. PubMed ID: 9010688
[TBL] [Abstract][Full Text] [Related]
4. l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial.
Domenech C; Thomas X; Chabaud S; Baruchel A; Gueyffier F; Mazingue F; Auvrignon A; Corm S; Dombret H; Chevallier P; Galambrun C; Huguet F; Legrand F; Mechinaud F; Vey N; Philip I; Liens D; Godfrin Y; Rigal D; Bertrand Y
Br J Haematol; 2011 Apr; 153(1):58-65. PubMed ID: 21332712
[TBL] [Abstract][Full Text] [Related]
5. Erythrocytes as carriers for L-asparaginase. Methodological and mouse in-vivo studies.
Kravtzoff R; Ropars C; Laguerre M; Muh JP; Chassaigne M
J Pharm Pharmacol; 1990 Jul; 42(7):473-6. PubMed ID: 1980286
[TBL] [Abstract][Full Text] [Related]
6. Infusion of red blood cell-loaded asparaginase in monkey. Immunologic, metabolic, and toxicologic consequences.
Updike SJ; Wakamiya RT
J Lab Clin Med; 1983 May; 101(5):679-91. PubMed ID: 6187874
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the rhesus monkey.
Berg SL; Balis FM; McCully CL; Godwin KS; Poplack DG
Cancer Chemother Pharmacol; 1993; 32(4):310-4. PubMed ID: 8324873
[TBL] [Abstract][Full Text] [Related]
8. Entrapment of L-asparaginase in red blood cells. A strategy to improve treatment of acute lymphoblastic leukemia.
Updike SJ
Bibl Haematol; 1985; (51):65-74. PubMed ID: 4004765
[TBL] [Abstract][Full Text] [Related]
9. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia.
Ahlke E; Nowak-Göttl U; Schulze-Westhoff P; Werber G; Börste H; Würthwein G; Jürgens H; Boos J
Br J Haematol; 1997 Mar; 96(4):675-81. PubMed ID: 9074406
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic tumor sensitivity to plasma L-asparagine starvation.
Dufour E; Gay F; Aguera K; Scoazec JY; Horand F; Lorenzi PL; Godfrin Y
Pancreas; 2012 Aug; 41(6):940-8. PubMed ID: 22513289
[TBL] [Abstract][Full Text] [Related]
11. Determination of parameters for enzyme therapy using L-asparaginase entrapped in canine erythrocytes.
Naqi A; DeLoach JR; Andrews K; Satterfield W; Keeling M
Biotechnol Appl Biochem; 1988 Aug; 10(4):365-72. PubMed ID: 3219195
[TBL] [Abstract][Full Text] [Related]
12. Gel entrapped L-asparaginase: kinetic behavior and antitumor activity.
O'Driscoll KF; Korus RA; Ohnuma T; Walczack IM
J Pharmacol Exp Ther; 1975 Nov; 195(2):382-8. PubMed ID: 241845
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal administration of carrier erythrocytes in dogs: an improved method for delivery of L-asparaginase.
DeLoach JR; Andrews K; Satterfield W; Keeling M
Biotechnol Appl Biochem; 1990 Jun; 12(3):331-5. PubMed ID: 2360993
[TBL] [Abstract][Full Text] [Related]
15. Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia.
Agrawal V; Woo JH; Borthakur G; Kantarjian H; Frankel AE
Protein Pept Lett; 2013 Apr; 20(4):392-402. PubMed ID: 23016580
[TBL] [Abstract][Full Text] [Related]
16. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.
Vieira Pinheiro JP; Wenner K; Escherich G; Lanvers-Kaminsky C; Würthwein G; Janka-Schaub G; Boos J
Pediatr Blood Cancer; 2006 Jan; 46(1):18-25. PubMed ID: 15929133
[TBL] [Abstract][Full Text] [Related]
17. Biological characterization of L-asparaginase liposomal formulations.
Gaspar MM; Perez-Soler R; Cruz ME
Cancer Chemother Pharmacol; 1996; 38(4):373-7. PubMed ID: 8674161
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future.
Avramis VI; Panosyan EH
Clin Pharmacokinet; 2005; 44(4):367-93. PubMed ID: 15828851
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols.
Vieira Pinheiro JP; Ahlke E; Nowak-Göttl U; Hempel G; Müller HJ; Lümkemann K; Schrappe M; Rath B; Fleischhack G; Mann G; Boos J
Br J Haematol; 1999 Feb; 104(2):313-20. PubMed ID: 10050714
[TBL] [Abstract][Full Text] [Related]
20. [Preliminary study on the safety and pharmacodynamic action of low dose L-asparaginase].
Wu ZL; Chen FX; Ye TZ; Lai YH; Cui YQ; Zou YW; Lu CY; Lan SL; Zhong GY; Guan JM; Wei FG; Zhang H
Zhonghua Xue Ye Xue Za Zhi; 2006 Jan; 27(1):14-6. PubMed ID: 16732932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
